PD-1/PD-L1 blockade, one of the most efficient immune checkpoint inhibitors (ICIs), is designed to inhibit the interaction between PD-1 and PD-L1, helping to restore the anti-cancer immune response, which was approved by USFDA as a first-line treatment for advanced EC. The gene discussed is CD274; the disease is cancer.